Hubro Therapeutics buys vaccine adjuvant from Targovax

Norwegian biotech company Targovax is in full swing with preparations for phase II studies with the drug candidate ONCOS-102. Following this spring’s collaboration agreement with American Agenus, the company is now selling its GM-CSF project to sector colleague Hubro Therapeutics for 10 MNOK. Hubro is taking over the project in its entirety in order to use in the development of its peptide-based cancer vaccines.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/11/hubro-therapeutics-buys-vaccine-adjuvant-from-targovax/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se